G
Genfit
Develops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases
About Genfit
A late-stage biopharmaceutical company dedicated to the discovery and development of therapeutic solutions for severe and chronic liver diseases. The company focuses on areas with high unmet medical needs, leveraging its expertise in liver disease to advance its pipeline of drug candidates.
Read full description
Genfit's business model is centered on the research and development of new drugs, from discovery to late-stage clinical trials. The company also engages in strategic partnerships and licensing agreements to commercialize its products and expand its research pipeline. A recent example is the licensing of the exclusive worldwide rights of the ASK1 Inhibitor SRT-015 from Seal Rock Therapeutics. The company's primary clients are patients suffering from rare and life-threatening liver diseases. Genfit operates in the global biopharmaceutical market, with a specific focus on hepatology.
At a glance
- Founded
- 1999
- Headquarters
- Loos, France
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Finorpa- CCCrede CapitalGroup
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
77 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genfit on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genfit on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.